Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors

#571

Introduction: Liver transplantation is an important option for patients of neuroendocrine tumors (NET) with metastases limited to the liver. Peptide receptor radionuclide therapy (PRRNT) is effective in the management of metastatic NET.

Aim(s): To assess safety and efficacy of PRRNT after liver transplantation in metastatic NET.

Materials and methods: This was a retrospective analysis in five patients (age 52±9 years; four males and one female) of NET with progressive extra hepatic metastatic disease after liver transplantation. None of the patients had evidence of recurrent disease in the transplanted liver. The patients received PRRNT with 3, 2, 2, 1 and 2 cycles respectively with Lu-177 alone, the cumulative administered activity ranging from 7.6 to 22.3 GBq after liver transplantation.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Hoersch D, Hommann M, Baum R,

Keywords: liver transplantation, peptide receptor radionuclide therapy,

To read the full abstract, please log into your ENETS Member account.